Fluoroquinolones: Action and Resistance
The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Abstract
Fluoroquinolones trap gyrase and topoisomerase IV on DNA as ternary complexes that block the movement of replication forks and transcription complexes. Studies with resistant mutants indicate that during complex formation quinolones bind to a surface alpha-helix of the GyrA and ParC proteins. Lethal action is a distinct event that is proposed to arise from release of DNA breaks from the ternary complexes. Many bacterial pathogens are exhibiting resistance due to alterations in drug permeability, drug efflux, gyrase-protecting proteins, and target topoisomerases. When selection of resistant mutants is described in terms of fluoroquinolone concentration, a threshold (mutant prevention concentration, MPC) can be defined for restricting the development of resistance. MPC varies among fluoroquinolones and pathogens; when combined with pharmacokinetics, MPC can be used to identify compounds least likely to enrich mutant subpopulations. Use of suboptimal doses and compounds erodes the efficacy of the class as a whole because resistance to one quinolone reduces susceptibility to others and/or increases the frequency at which resistance develops. When using fluoroquinolones in combination therapy, the development of resistance may be minimized by optimizing regimens for pharmacokinetic overlap.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
The complete genome sequence of the gastric pathogen Helicobacter pylori
Tomb, J.-F., White, O., Kerlavage, A. R., Clayton, R. A., Sutton, G. G., Fleischmann, R. D., Ketchum, K. A., Klenk, H. P., Gill, S., Dougherty, B. A., et al. (1997) · Nature · doi:10.1038/41483 · Cited by 3,529 · cited 1×
“The human pathogens Mycobacterium tuberculosis, Helicobacter pylori, and Treponema pallidum represent a class that appears to have only gyrase as a target, since the genomes of these organisms lack a gene encoding topoisomerase IV [116-118].”
BackgroundCraig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“For fluoroquinolones, the empirical pharmacodynamic indices AUC/MIC and Cmax/MIC are related to favorable patient outcome with some infections [196, 197].”
BackgroundDNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Supercoiling of the DNA template during transcription.
Liu, L. F., & Wang, J. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7024 · Cited by 1,962
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Self-citationDNA gyrase: an enzyme that introduces superhelical turns into DNA.
Gellert, M., Mizuuchi, K., O'Dea, M. H., & Nash, H. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3872 · Cited by 1,204
Quinolone resistance from a transferable plasmid
Martínez-Martínez, L., Pascual, A., & Jacoby, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07322-4 · Cited by 1,100
Complete Genome Sequence of Treponema pallidum, the Syphilis Spirochete
Fraser, C. M., Norris, S. J., Weinstock, G. M., White, O., Sutton, G. G., Dodson, R., Gwinn, M., Hickey, E. K., Clayton, R., Ketchum, K. A., et al. (1998) · Science · doi:10.1126/science.281.5375.375 · Cited by 1,081
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
Cited by
Fluorine in Pharmaceuticals: Looking Beyond Intuition
Müller, K., Faeh, C., & Diederich, F. (2007) · Science · doi:10.1126/science.1131943 · Cited by 6,596
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Molecular Mechanisms of Antibacterial Multidrug Resistance
Alekshun, M. N., & Levy, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.03.004 · Cited by 1,647
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
The changing epidemiology of resistance
Hawkey, P. M., & Jones, A. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp256 · Cited by 773
Acceleration of Emergence of Bacterial Antibiotic Resistance in Connected Microenvironments
Zhang, Q., Lambert, G., Liao, D., Kim, H., Robin, K., Tung, C.-K., Pourmand, N., & Austin, R. H. (2011) · Science · doi:10.1126/science.1208747 · Cited by 539
Role of reactive oxygen species in antibiotic action and resistance
Dwyer, D. J., Kohanski, M. A., & Collins, J. J. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.06.018 · Cited by 484
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Heym, B., Philipp, W., & Cole, S. T. (1996) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-80166-2_3 · Cited by 379
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Self-citationShort-Term Effect of Antibiotics on Human Gut Microbiota
Panda, S., El khader, I., Casellas, F., López Vivancos, J., García Cors, M., Santiago, A., Cuenca, S., Guarner, F., & Manichanh, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095476 · Cited by 349
Jiang, C., Ji, Y., Shi, Y., Chen, J., & Cai, T. (2016) · Water Research · doi:10.1016/j.watres.2016.10.025 · Cited by 325
A Fluoroquinolone Resistance Protein from Mycobacterium tuberculosis That Mimics DNA
Hegde, S. S., Vetting, M. W., Roderick, S. L., Mitchenall, L. A., Maxwell, A., Takiff, H. E., & Blanchard, J. S. (2005) · Science · doi:10.1126/science.1110699 · Cited by 291
DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents
Khan, T., Sankhe, K., Suvarna, V., Sherje, A., Patel, K., & Dravyakar, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.021 · Cited by 253
Recent Advances in the Chemistry and Biology of Naturally Occurring Antibiotics
Nicolaou, K. C., Chen, J. S., Edmonds, D. J., & Estrada, A. A. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200801695 · Cited by 225
Metadata
- Authors
- Drlica, K., & Malik, M.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-01-01
- Volume
- 3
- Issue
- 3
- Pages
- 249-282
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2118813171
- Cited by
- 317
- References
- 158
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.